Skip to main content

Table 5 Results of the multivariate analyses of locoregional control, metastases-free survival and overall survival

From: Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers

  Hazard ratio 95 %-confidence interval P
Locoregional control
 Radiochemotherapy regimen
  (Cisplatin 100 mg/m2 vs. Cisplatin weekly) 1.57 1.12–2.31 0.008
 Gender
  (female vs. male) 4.37 1.58–18.11 0.003
 Primary tumor site
  (oropharynx or larynx vs. others) 1.18 0.94–1.45 0.16
Metastases-free survival
 ECOG performance score
  (0–1 vs. 2) 5.63 2.19–14.11 <0.001
 N-category
  (N0-2a vs. N2b-3) 2.02 0.90–4.84 0.09
 Histological grading
  (G1–2 vs. G3) 1.81 1.26–2.66 0.002
 Primary tumor site
  (oropharynx or larynx vs. others) 1.15 0.88–1.50 0.30
Overall survival
 Radiochemotherapy regimen
  (Cisplatin 100 mg/m2 vs. Cisplatin weekly) 1.33 1.04–1.73 0.023
 Gender
  (female vs. male) 1.98 1.08–3.96 0.026
 ECOG performance score
  (0–1 vs. 2) 2.15 1.09–3.99 0.029
 Primary tumor site
  (oropharynx or larynx vs. others) 1.09 0.92–1.30 0.32
  1. Bold values represent significant p-values